COL11A1 and neoplasm: In ovarian cancer, PRRX1 enhances tumor progression and resistance to chemotherapy and radiotherapy by activating COL11A1 (Wu et al., 2019; Zhu et al., 2021a; Heiserman et al., 2021), and miR-335 inhibits the invasion and migration of ovarian cancer cells by inhibiting the expression of COL11A1 (Wu et al., 2021a).